Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Double-blind, Double-dummy, Randomised, Multicentre, Comparative Study of the Efficacy and Tolerability of Once Daily 3.0 g Mesalazine Granules Versus Three Times Daily 1.0 g Mesalazine Granules in Patients With Active Ulcerative Colitis

NCT00449722 is registered in ClinicalTrials.gov with Dr. Falk Pharma GmbH as lead sponsor.

NCT NCT00449722
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00449722 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Double-blind, Double-dummy, Randomised, Multicentre, Comparative Study of the Efficacy and Tolerability of Once Daily 3.0 g Mesalazine Granules Versus Three Times Daily 1.0 g Mesalazine Granules in Patients With Active Ulcerative Colitis
Lead sponsor
Dr. Falk Pharma GmbH
Phase
Phase 3
Overall status
Completed
Start date
July 31, 2005
Completion date
June 30, 2006
Enrollment
380
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

ulcerative colitis